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Oxidation of low-density lipoprotein (LDL) is thought to be a major factor in the pathophysiology of atherosclerosis. Elevated plasma
homocysteine is an accepted risk factor for atherosclerosis, and may act through LDL oxidation, although this is controversial. In this study,
homocysteine at physiological concentrations is shown to act as a pro-oxidant for three stages of copper-mediated LDL oxidation (initiation,
conjugated diene formation and aldehyde formation), whereas at high concentration, it acts as an antioxidant. The affinity for copper of
homocysteine and related copper ligands homocysteine, cystathionine and djenkolate was measured, showing that at high concentrations
(100 AM) under our assay conditions, they bind essentially all of the copper present. This is used to rationalise the behaviour of these ligands,
which stimulate LDL oxidation at low concentration but generally inhibit it at high concentration. Albumin strongly reduced the effect of
homocystine on lag time for LDL oxidation, suggesting that the effects of homocystine are due to copper binding. In contrast, copper binding
does not fully explain the pro-oxidant behaviour of low concentrations of homocysteine towards LDL, which appears in part at least to be due
to stimulation of free radical production. The likely role of homocysteine in LDL oxidation in vivo is discussed in the light of these results.
D 2003 Elsevier B.V. All rights reserved.Keywords: Homocysteine; Cardiovascular disease; Citrate; LDL; Pro-oxidant; Antioxidant1. Introduction
There is a well-established epidemiological relationship
between total plasma homocysteine concentration (tHcy)
and cardiovascular disease [1–4]. It has been estimated that
10% of the population risk for cardiovascular disease in the
US is associated with elevated tHcy [5]. Elevated tHcy is
linked to increased risk of cardiovascular disease to a
similar extent to that of smoking and hyperlipidaemia,
and strengthens the link between smoking and hypertension
[6]. Various explanations have been put forward to account
for these associations, including a pro-oxidant role for tHcy
in vivo. It has been hypothesised for example that tHcy
stimulates the oxidation of low-density lipoprotein (LDL)
lipid. Oxidatively damaged LDL are considered atherogenic.0925-4439/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2003.10.005
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E-mail address: h.j.powers@Sheffield.ac.uk (H.J. Powers).The oxidised lipid would tend to form atherosclerotic
plaques and so promote cardiovascular disease. The evi-
dence for or against this hypothesis is confused. A number
of studies, primarily in vitro, suggest that tHcy does pro-
mote oxidation of LDL [7–15]. Other studies, however,
suggest that tHcy does not promote oxidation of LDL, and
may even act to protect LDL against oxidation [16–18].
Interpretation of the results of these studies is complicated
by the fact that in vivo (and in in vitro assays) most
homocysteine (HcySH) is rapidly oxidised to homocystine
(HcySS) or to mixed disulfides, leaving only approximately
1% as free HcySH [19].
Neither the site of oxidative damage to LDL nor the
mechanisms involved in vivo are understood. The majority
of studies of LDL oxidation in vitro [10,20,21] have used
transition metal-dependent (usually copper) systems, al-
though some have used organic free radical generators
[22] or enzymatic systems [23]. We concentrate here on
the role of homocysteine and related compounds on copper-
mediated oxidation. A complex set of reactions is involved,
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and include at least the following [25,26]:
Cu2þ þ RSH! Cuþ þ RSS þ Hþ
2RSS ! RSSR
Cuþ þ O2 ! Cu2þ þ OS2
or
Cuþ þ O2 ! CuOþ2
CuOþ2 þ Hþ ! Cu2þ þ HO2
HO2 þ Cuþ ! Cu2þ þ HO2
HO2 þ Hþ ! H2O2
The reactive oxygen species (ROS) so produced then
oxidise LDL. LDL is made up of protein and lipid, which
latter contains a number of small molecules including
cholesterol and tocopherol (vitamin E). In this study, we
concentrate on oxidation of the lipid component. There is
general agreement that the first stage in oxidation of LDL
lipid is oxidation of tocopherol and carotenoids [27,28].
Following this stage, polyunsaturated fatty acids are oxi-
dised to conjugated dienes. Further oxidation leads to the
formation of the peroxyl radical which goes on to form lipid
hydroperoxides (and cyclic peroxides) which can decom-
pose to form aldehydes, including malondialdehyde (MDA)
[29]. Compounds which lengthen the period preceding the
maximum rate of peroxidation (the ‘lag phase’) are consid-
ered as antioxidants. LDL lipid peroxidation can be moni-
tored in vitro in a number of ways, including the
measurement of conjugated dienes, and MDA formation.
Lag times for diene and aldehyde formation have often been
found to be similar [30,31]. The complexity of these
reactions, particularly in plasma, where there are many other
molecules present that may interfere, means that different
researchers have come to very different conclusions about
the effects of homocysteine towards LDL. We therefore
concentrate here on exploring a simple but moderately
realistic system, to show how LDL oxidation is affected
by homocysteine and other related compounds, and the
putative mechanisms involved.2. Materials and methods
2.1. Materials
Chemicals were purchased from Sigma Chemical Co.,
Poole, Dorset, UK except where stated otherwise.2.2. LDL preparation
Fasted blood was collected from a healthy volunteer
into lithium heparin, and centrifuged at 4 jC at 1000 g
for 15 min to remove cells. LDL was isolated from the
plasma by centrifugation through iodixanol (Liposep, Lip-
otek Ltd., Liverpool, UK), using a method modified from
Graham et al. [32]. Plasma was mixed with iodixanol in
Hepes-buffered saline (HBS) (0.14 M NaCl, 10 mM
Hepes, pH 7.4) to make a 12% iodixanol solution. This
was layered underneath a 9% iodixanol solution and
centrifuged for 2.5 h at 16 jC at 100,000 rpm in an
Optima Max-E centrifuge. The fractions containing LDL
were separated using a Gilson FC 205 fraction collector
and pooled. At this stage, fractions could be flushed with
nitrogen and kept at 4 jC until use for at least a week
without any measurable increase in lipid oxidation, mea-
sured as diene formation. To remove iodixanol and low
molecular weight endogenous antioxidants, the solution
was passed under gravity flow through a 1.0 30 cm
column of Sephadex G-25, eluted with HBS. The choles-
terol concentration of the isolated LDL preparation was
measured using a cholesterol oxidase assay.
2.3. LDL lipid oxidation
For LDL oxidation assays, all LDL preparations were
diluted with HBS to 100 Ag LDL protein/ml (162 Ag
cholesterol/ml). Oxidation was initiated by the addition of
CuSO4 (final Cu concentration 30 AM), approximating that
in plasma [33], and sodium citrate (final concentration 360
AM), and carried out at 37 jC. These conditions were
designed to approximate in vivo copper availability (see
Discussion). The total time between passage through the
Sephadex column and start of the incubation with copper
was less than 1 h.
Oxidation of LDL lipids to conjugated dienes was
measured by continuous monitoring of the absorbance at
234 nm [34]. The LDL suspension was incubated in a quartz
cuvette, and the absorbance measured at 234 nm against a
blank of HBS, using a Camspec M330 single beam UV/
Visible spectrophotometer operating at 37 jC. The molar
concentration of diene present was calculated using a molar
extinction coefficient of 2.52 104 M 1 cm 1 [34]. Oxi-
dation of LDL to MDA was measured by monitoring the
product of reaction with thiobarbituric acid, using the
TBARS assay [18,34]. All incubations were carried out in
1.5 ml screw-capped Eppendorf tubes, in a volume of 0.4
ml. After the incubation of LDL, butylated hydroxytoluene
(final concentration, 500 AM) and diethylenetriaminepenta-
acetic acid (DTPA) (final concentration, 1 mM) were added
to prevent further oxidation. A stock solution of 15% w/v
trichloroacetic acid, 0.38% w/v thiobarbituric acid, and 0.25
N hydrochloric acid was prepared, and 0.8 ml of this was
added to the LDL suspension, which was heated for 15 min
at 100 jC. The suspension was then cooled and centrifuged
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(ca. 0.8 ml) was placed in a cuvette, the absorbance at 532
and 580 nm was measured, and the difference in absorbance
(A532–A580) determined. Concentrations of MDA were
calculated using an extinction coefficient of 1.56 105
M 1 cm 1 [18].
LDL lipid oxidation, measured as dienes or TBARS,
was plotted as a function of incubation time. The kinetics
of LDL lipid oxidation were analysed in terms of the lag
time prior to oxidation, using the graphical method of
McDowell et al. [31], implemented in a macro specially
written for the Camspec. The tangent to the curve was
taken at the steepest part of the slope, and extrapolated
back to the baseline absorbance. The baseline absorbance
was taken as the absorbance preceding the steep rise in
absorbance.
2.4. Effects of homocysteine and related compounds on LDL
oxidation
L-Homocysteine was prepared from L-homocysteine
thiolactone [35]. Homocysteine thiolactone (0.05 mmol)
was mixed with 0.15 ml of 5 M NaOH and incubated for
5 min at room temperature. 0.75 ml of 1.0 M KH2PO4
was added to the solution and diluted to a volume of 10
ml with water, to give a stock solution of 5 mM
homocysteine at neutral pH, which was stored under N2
at  20 jC. The solution was diluted in HBS to 1 mM
before use. Homocysteine was added to the LDL suspen-
sion immediately before oxidation was initiated with
copper, to a final homocysteine concentration of 5, 10,
50 and 100 AM. In order to explain observed effects of
homocysteine on LDL oxidation, experiments were also
carried out in the presence of L-homocystine, DL-djenko-
late and L-cystathionine, all of which are potential copper
ligands. These compounds were made up as stock sol-
utions in 1 M HCl, because of their low solubility at
neutral pH, and added to the LDL reaction mixture to
give final concentrations of 10 and 100 AM. The resultant
change in pH was less than 0.1 pH units and is calculated
(Hyperquad2000) to have negligible effect on copper
binding.
2.5. Copper-binding affinities of homocysteine and related
compounds (ligands)
The most convenient way to measure copper-binding
affinities is to measure pK values in the absence of copper,
and then repeat the measurement in the presence of copper.
Copper competes with H+ for binding to the ligand, and
therefore affects the pK. Binding affinities can be obtained
by fitting the pK titration curve.
Affinities for copper were measured by pH titration of
the ligand starting from pH< 2 and titrating with 1 M
sodium hydroxide. Ligand concentrations were 4 mM in
10 ml, except where insolubility at pH>6 necessitatedreducing the concentration to 1, 0.5 or 0.1 mM: in this
case, the sodium hydroxide concentration was also reduced.
Measured pH values were fitted to a model involving three
(citrate, cystathionine, HcySH) or four (djenkolate, HcySS)
pK values: inclusion of additional pK values where relevant
gave worse fits. Titrations were then repeated in the
presence of equimolar concentrations of copper. The fitting
used the pK values in the absence of copper as fixed, and
included Cu.L, H.Cu.L (all), H2.Cu.L (cystathionine, djen-
kolate, homocystine), L2.Cu (all except citrate and djenko-
late) as the species present: again, addition of extra species
gave worse fits. All fitting and subsequent speciation
calculations were done using the program Hyperquad2000
[36].
2.6. Statistical analysis
Statistical tests were carried out using SPSS for Win-
dows 10.0. Because of the small number of experiments for
each set of conditions (generally four or five), non-para-
metric tests were used. The Kruskal–Wallis test was used
to determine whether homocysteine concentration influ-
enced lag times, after which the Mann–Whitney U-test
was used to compare specific pairs of conditions. A post
hoc Tukey one-way ANOVA gave similar results. As data
are not normally distributed, they are displayed as medians
and ranges.3. Results
3.1. Copper-mediated LDL oxidation
Previous workers have suggested that the LDL prepara-
tion has to be as fresh as possible, without hydroperoxides
[31], and that the copper should be chelated reasonably
strongly, since a simple hydrated copper ion binds prefer-
entially to phosphate, chloride, etc., which leads to mark-
edly different oxidation rates with small changes in buffer
composition [37]. On the other hand, chelation by a tight
ligand such as EDTA reduces the oxidation rate strongly
[31]. We therefore followed Schnitzer et al. [14,37] and used
citrate in the assay buffer, which binds copper moderately
tightly and prevents precipitation. We also used a method
for purifying LDL that takes less than 5 h from collection of
blood. Partially purified samples could be kept at 4 jC
under nitrogen for several days without any obvious effect.
For most measurements, storage at 4 jC for a week gave
little if any change in the lag time (Fig. 1A). By far the most
marked time dependence was seen for measurements made
in the presence of 100 AM HcySS, where storage even for 2
days gave a large reduction in lag time (Fig. 1B). Most
measurements were therefore carried out within 3 days of
blood collection. The final purification step, involving rapid
gel filtration chromatography, was always carried out within
1 h of starting the assay. When LDL was prepared in this
Fig. 2. Effect of homocysteine on (A) LDL oxidation measured using the
conjugated diene assay in the presence of citrate and copper (30 AM). The
values shown are results of a single typical experiment. (B) Time for
formation of conjugated diene in LDL lipid, calculated as the time taken for
absorbance at 234 nm to go from near baseline to near maximum. Values
shown are medians and ranges.
Fig. 1. Dependence of lag time for LDL oxidation on duration of storage of
the partially purified LDL at 4 jC under nitrogen. The figure shows results
for lag times measured using (A) standard buffer, and (B) standard buffer
plus 100 AM HcySS. The trend line has R2 = 0.66.
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no more than 10 min from one preparation to another, in
fasted blood samples from the same individual. On leaving
the LDL for 2 h between the removal of endogenous
antioxidants by Sephadex chromatography and the start of
the incubation, the lag time decreased to approximately 70
min, indicating that significant oxidation occurs even over
this short time in the absence of copper once low molecular
weight antioxidants have been removed.
3.2. Effects of homocysteine on LDL oxidation
3.2.1. Oxidation to conjugated diene
Fig. 2A shows the kinetics for the copper-mediated
oxidation of LDL lipid measured using the conjugated diene
assay, over a range of concentrations of HcySH from 0 to
100 AM. Typical of LDL oxidation, there was a lag time,
during which absorbance increased slowly, followed by a
rapid increase to a maximum value. The typical maximum
change in absorbance was approximately 1.2 AU, which
corresponds to a change in concentration of conjugated
diene of ca. 47 AM. The estimated total concentration of
polyunsaturated fatty acid in this LDL preparation was 42
AM, based on typical LDL compositions [38], and therefore
the change seen suggests that essentially all the polyunsat-
urated fatty acid present has been oxidised to conjugateddiene. A slow subsequent loss in signal intensity at low
concentrations of HcySH presumably reflects further oxida-
tion of conjugated dienes [16,39]. It is clear that lag times
vary markedly as a function of HcySH concentration, but so
do the times for the complete oxidation to dienes, which
show a small reduction at low (HcySH) followed by an
increase at higher concentration (Fig. 2B).
3.2.2. Oxidation to malondialdehyde
Fig. 3A shows profiles for MDA formation during LDL
oxidation in the presence of different concentrations of
HcySH. The general oxidation profile is similar to that of
the conjugated diene (Fig. 2A). The maximum change in
absorbance was approximately 0.3 AU, corresponding to a
concentration change of 6 AM. MDA is thought to be
produced almost entirely from tri-unsaturated fatty acids
[34], which on the basis of the average composition of LDL,
have an estimated concentration in this preparation of
approximately 8 AM and consist almost entirely of linolenic
acid [38].
The lag times for oxidation of LDL lipid to conjugated
diene and TBARS were calculated, and are shown in Table
1 and compared in Fig. 3B. Effects of homocysteine were
qualitatively similar for both stages of lipid oxidation in that
low concentrations (5 and 10 AM) speeded up oxidation
Fig. 4. Effects of homocysteine at different concentrations on the lag times
for copper-mediated oxidation of LDL lipid from conjugated diene to MDA
using data from Fig. 3B. This is expressed as the difference between the
median lag times for absorbance at 234 nm and TBARS, with the upper and
lower limits.
Fig. 3. Effect of homocysteine on (A) LDL oxidation measured using the
TBARS assay in the presence of citrate and copper (30 AM). The values
shown are results of a single typical experiment. (B) Lag times for
formation of conjugated dienes and TBARS from LDL in the presence of
citrate and copper (medians and ranges for nz 4). The inset shows an
expansion of the graph for low concentrations of homocysteine. For
TBARS at 50 and 100 AM homocysteine, there is no defined upper limit as
in some experiments, no oxidation was seen even in the final sample
collected.
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oxidation. Diene formation in the presence of all concen-
trations of homocysteine was significantly different from the
control (P < 0.05). The formation of TBARS at 10, 50 and
100 AM homocysteine was significantly different from the
control (P < 0.05), while 5 AM just failed to reach statistical
significance (P= 0.059). Higher concentrations of homo-
cysteine had a more marked effect on the lag times for
formation of TBARS than for conjugated dienes, suggesting
that the oxidation of dienes to MDA and other aldehydes isTable 1









0 126 (4) 171 (4)
5 64 (5) 127 (4)
10 115 (4) 123 (4)
50 335 (5) 880 (8)
100 586 (6) 1450 (4)
Values in parentheses indicate the number of measurements.inhibited by high concentrations of HcySH. The time taken
for this stage is simply the time difference between the lag
times for the conjugated diene and TBARS assays, and is
shown in Fig. 4.
3.2.3. Effect of homocystine, cystathionine and djenkolate
Most homocyst(e)ine in the circulation exists in oxi-
dised forms, with only about 1% found as free HcySH,
but with an increasing proportion in the reduced form as
total concentrations rise [40,41]. We therefore measured
the effect of HcySS/HcySH mixtures on LDL oxidation,
as measured by the lag time in conjugated diene assays.
Homocystine had a marked effect on the lag time, which
in general was reduced at 10 AM HcySS and greatly
increased at 100 AM (Table 2). These results are non-
intuitive, and therefore to further explore the likely
mechanisms of the effects of HcySH and HcySS, we
carried out measurements using cystathionine [HO2C-
CH(NH2)-CH2-CH2-S-CH2-CH(NH2)-CO2H] or djenko-
late [HO2C-CH(NH2)-CH2-S-CH2-S-CH2-CH(NH2)-
CO2H], since these compounds are similar in structure
to HcySS but cannot be reduced to thiols or allow the
formation of RSSRV S radical anion. Cystathionine and
djenkolate also had complex effects on the lag time
(Table 3), with both compounds producing a shorter
lag time at 10 AM and djenkolate producing a longer
lag time at 100 AM.Table 2
Effects of homocysteine/homocystine mixtures on lag times (mins) for Cu-
mediated LDL oxidation
Homocystine (AM) Homocysteine (AM)
0 1 5 10
0 161F 6 145F 4 86F 9 106F 9
10 46 F 5 82F 4 88F 30 102F 10
100 397F 115 239F 79 245F 107 307F 45
Results are given as medians and ranges of between three and seven
independent measurements.
Table 4
Copper-binding behaviour of homocysteine and related compounds
Log(h) Citrate Hcy HcySS Cystathionine Djenkolate
LH 5.73 9.1 9.1 9.39 9.5
LH2 10.19 18.7 17.7 18.0 18.1
LH3 13.36 26.0 20.5 21.3 23.7
LH4 – – 22.5 – 26.1
LCu 4.38 5.6 8.3 9.91 9.1
LCuH 8.36 13.5 15.9 19.62 19.5
LCuH2 – 23.5 – 27.78 24.6
L2Cu – 11.0 14.3 19.21 –
L2CuH – 18.6 – – –
h is the association constant between all the ligands shown in the table.
Therefore, individual binding constants can be obtained by subtraction of
constituent log(h) values. For example log(h) for LH formation is equal to
the first pK value, while log(h) for LH2 formation is equal to the sum of the
first two pK values. Similarly, log(h) for LCu formation is the association
constant between fully deprotonated ligand and copper, while log(h) for
LCuH formation is the sum of the above association constant and the first
pK of LCu.
Table 3
Effects of cystathionine and djenkolate on lag times (mins) for Cu-mediated
LDL oxidation
X Control 10 AM X 100 AM X
Cystathionine 174F 18 133F 6 107F 5
Djenkolate 151F 0 138F 8 184F 7
Measurements of control, 10 and 100 AM were made on the same sample at
the same time, and repeated two or three times on different samples to obtain
the results quoted in the table. Results are given as medians and ranges.
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cystathionine and djenkolate
Cystathionine and djenkolate are most likely to affect the
lag time for LDL oxidation via binding to copper, since they
are expected to be unreactive in redox chemistry but have
strong affinity for copper. We therefore measured the
affinity for copper(II) of HcySH, HcySS, cystathionine,
and djenkolate. This was done in the standard way, namely
by measuring the effect of copper on pK values. Each
compound was adjusted to low pH with HCl, and titrated
with NaOH. The values of pH against volume of NaOH
added (Fig. 5A) were used to fit pK values (Table 4). TheFig. 5. (A) pH Titration curve of cystathionine. Cystathionine (1 mM) in 10
ml dilute HCl was titrated with 1 M NaOH. Experimental points are shown
by diamonds, and the fitted curve is shown, with the fitted values given in
Table 1. The x coordinates describe additions of NaOH, which were not all
of the same volume. (B) Titration curve of 1 mM cystathionine, 1 mM
copper sulfate with 1 M NaOH.titration was then repeated in the presence of equimolar
amounts of Cu2 + (Fig. 5B). The previously fitted pK values
were kept constant, and the curves were fitted to obtain
values of the copper affinities for each complex, shown in
Table 4 as the log of the association constant for each
complex. These results are approximate, since a limited
range of concentrations was used, and many of the fitted
values are highly correlated. However, the fitted values are
reasonably self-consistent, and where literature values are
available [42], the match is good.
3.4. Effect of albumin
The results reported in Tables 2–4 demonstrate that
HcySH, HcySS and its analogs bind strongly to copper
and also affect the lag time for LDL oxidation. In vivo, most
copper is bound to ceruloplasmin and albumin [43]. Addi-
tion of albumin at normal in vivo concentrations (30–45
mg/ml) causes so much background signal that our assays of
LDL oxidation could not be used. We therefore used a much
lower albumin concentration, 0.5 mg/ml. Even at these low
concentrations, there are effects on lag times in the presence
of HcySH and particularly of HcySS (Table 5). In the
absence of HcySS, albumin acts merely to increase the lag
time. However, in the presence of HcySS, albumin appears
to act to moderate the effect of HcySS, by altering the lag
time in the direction of that seen in the absence of HcySS.Table 5
Modulating effect of albumin on lag times (mins) for homocyst(e)ine-
mediated LDL oxidation
Homocystine (AM) Homocysteine (1 AM) Homocysteine (5 AM)
Hcy +Albumin Hcy +Albumin
0 142F 4 143F 3 86F 9 116F 7
10 82F 2 125F 6 88F 30 113F 1
100 239F 79 252F 28 245F 107 157F 1
Results are given as medians and ranges for three different experiments.
Fig. 6. Thermodynamic cycle for copper reduction and ligand binding. The
total change in free energy from upper left to lower right is independent of
the pathway taken, implying that the relatively strong binding of the more
highly charged Cu2 + to X necessitates a less energetically favourable
reduction of Cu2 +.X to Cu+.X than of Cu2 + to Cu+.
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4.1. Three phases of LDL lipid oxidation
Almost all studies of LDL lipid oxidation have observed
a lag phase [39,44], which is considered to reflect the period
of depletion of endogenous antioxidants [28,45], as well as
a period of autocatalytic formation of lipid peroxides, which
are thought to be key initiators of subsequent oxidative steps
[46,47]. Here we have shown clearly for the first time that,
as expected, the formation of conjugated dienes is a clearly
differentiated step that precedes the formation of TBARS.
Further, we have shown that HcySH at concentrations V 10
AM shortens the lag time for each phase, while at concen-
trations >10 AM it increases the lag time. Under the
conditions of our assay, HcySH clearly behaves as a pro-
oxidant at concentrations < 10 AM, and an antioxidant at
higher concentrations.
This behaviour is similar to that observed by Halvorsen
et al. [22], but different from that seen in most other studies.
There are several explanations. Some studies merely mea-
sured the amount of conjugated diene produced after 24-
h oxidation [7,8,10]. As can be seen from Fig. 2A, this is
likely to produce misleading results, because whatever the
lag time of LDL lipid oxidation, the maximal change in
absorbance is always approximately the same. However,
after reaching its maximum, absorbance at 234 nm slowly
falls because of further oxidation and loss of conjugated
dienes. Therefore, a single measurement made at 24 h may
in fact give a smaller absorbance value for a faster oxida-
tion. The use of citrate to bind to copper (discussed below)
and very rapidly purified LDL in our experiments may also
be a factor explaining the difference between our results and
some others. Most previous studies have used much longer
LDL preparation times, probably associated with significant
oxidation before the start of incubation. This would make
further oxidation harder to interpret, and could lead to
problems from autocatalytic oxidation of LDL lipid
[48,49]. One of the few other studies to see an inhibition
of LDL oxidation by homocysteine (at 1000 AM) also used
a very rapid LDL preparation, resulting in unoxidised LDL
at the start of incubation [50]. Storage of LDL evidently
does influence susceptibility to oxidation in vitro, but this
was particularly evident only in the presence of 100 AM
HcySS. Our storage times were short and results were
reproducible, suggesting that our LDL preparations were
reasonably free from hydroperoxide.
4.2. Copper chelation
Cystathionine and djenkolate can only have any effect on
LDL oxidation by binding to copper, and, assuming that
there is nothing in the incubation buffer that can reduce it to
homocysteine, homocystine can also only act by binding to
copper. The results in Table 4, taken together with results
shown in Tables 2–3, show that binding to copper has majoreffects on the lag time for conjugated diene formation. At
high concentrations (100 AM), homocystine and djenkolate
lead to an increase in lag time. At these concentrations, over
95% of the copper is bound into complexes (calculated
using the fitted association constants by Hyperquad2000
[36]). It has been shown that binding of EDTA to copper
results in a marked slowing of copper-mediated LDL
oxidation [31], and it would not be surprising if binding
to other ligands had a similar effect.
The favourable free energy of binding copper to a ligand
also makes the reduction of copper(II) to copper(I) less
favourable, as shown by a thermodynamic cycle (Fig. 6).
Thus, ligand binding of copper not only makes copper less
available for oxidation reactions, it also makes it harder to
reduce copper.
However, we have also found that 10 AM concentrations
of homocystine, djenkolate or cystathionine reduce the lag
time for production of conjugated dienes. At 10 AM ligand,
approximately 10% of the copper present is free, and the
remainder is distributed among a range of complexes. There
is nothing in the nature of the complexes to explain the
decrease in lag time. A number of hypotheses can be put
forward to explain the results. One of the suggested subse-
quent reactions is the generation of ROS, for example by
reactions of the type
X:Cuþ þ O2 ! X:Cu2þ þ OS2
where X represents one of the negatively charged ligands
homocystine, djenkolate or cystathionine. It is likely that the
ligands, by stabilising the more coulombically favourable
X.Cu2 + complex, promote the formation of ROS and thus
reduce the lag time.
Copper chelation can therefore have major effects on the
rate of LDL oxidation, either reducing or increasing it. This
supports the findings of previous workers, who found that
one source of confusion in earlier experiments was the lack
of chelating species in the buffer, with the result that, for
example, chloride in the buffer bound to Cu2 + and Cu+
differentially, thereby affecting oxidation rates [37]. For this
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a high concentration [14]. In the absence of homocysteine,
addition of citrate caused an increase in lag time (data not
shown), consistent with citrate complexing to copper [37].
Furthermore, lag times measured using conjugated diene
and MDA assays in the absence of citrate followed no
logical or consistent pattern (data not shown), whereas in the
presence of citrate the lag times are readily interpretable.
4.3. Effect of albumin and homocysteine on LDL oxidation
Homocysteine causes a decrease in lag time at low
concentration and an increase at high concentration. Similar
effects are produced by homocystine and djenkolate. The
question therefore arises: are the effects of homocysteine
due merely to copper binding, and not to free radical
mechanisms? We have three reasons for thinking that free
radical mechanisms are responsible.
First, there is extensive evidence that free radicals and
ROS are formed during incubations of LDL with transition
metals, and that the oxidative damage is consistent with the
presence of free radicals [7,20,51]. Second, homocysteine
has only relatively weak binding to copper. From the
binding constants measured (Table 4) and the concentrations
used in the assay, we calculate that when only copper and
citrate are present, 11% of the copper is free and 89% is in
the form of a copper–citrate complex. When 10 AM
homocysteine is added, there is a modest reduction in the
amount of the copper–citrate complex, to 86%, and 3% of
the copper is present as a Cu.homocysteine.H2 complex.
The third reason derives from the results of LDL oxida-
tion in the presence of 0.5 mg/ml albumin. Albumin binds
copper, and should reduce the influence of copper binding
on LDL oxidation. In agreement with this, albumin sub-
stantially reduces the effect of HcySS on lag time, even
when it is only present at 0.5 mg/ml (Table 5). By contrast,
it has little influence on the effect of HcySH, merely leading
to an increase in the lag time, most likely due to chelation of
free copper [44]. Thus, it has a much greater influence over
effects clearly ascribable to copper binding than it does on
HcySH, implying that HcySH does not act merely through
copper binding.
4.4. Relevance to the in vivo situation
What do these results tell us about the role of homo-
cyst(e)ine in vivo? In healthy individuals, the plasma total
homocyst(e)ine range is 5–15 AM, of which the concen-
tration of homocysteine itself is only about 1% [41]. A
moderate elevation in plasma homocysteine (15–50 AM) of
various etiology has been associated with an increased risk
of premature cardiovascular disease in the general popula-
tion [52]. In subjects homozygous for cystathione h syn-
thase deficiency, for whom there is an increased risk of
cardiovascular disease, the total homocyst(e)ine concentra-
tion commonly rises over 200 AM and the homocysteineconcentration over 10 AM [40]. The concentration of copper
in plasma is similar to that used here, but 95% of it is bound
by ceruloplasmin, most of the rest being bound by albumin
[44]. However, it has been shown that ceruloplasmin-bound
copper behaves very similarly to copper in simple com-
plexes (for example, complexes with citrate, as used here),
possibly because in ceruloplasmin one of the eight bound
copper atoms is accessible to the surface and is therefore
available for redox reactions [53,54]. Thus, although most
of our experiments did not use ceruloplasmin or albumin to
bind copper, the use of citrate is a reasonably physiological
surrogate. Extrapolating from our results with albumin, the
Cu-binding effect of homocystine in plasma is therefore
likely to be insignificant, and consequently homocystine is
unlikely to influence LDL oxidation in vivo. We conclude
that the conditions of our assay are sufficiently close to the
in vivo conditions for the results to be relevant. We find that
in concentrations up to 10 AM (i.e., over all the range
accessible in vivo), homocysteine acts as a pro-oxidant for
LDL. This agrees with the majority of studies of homo-
cysteine [7–15], and supports the hypothesis that homo-
cysteine is an independent risk factor for cardiovascular
disease because it stimulates oxidation of LDL lipid [55].
The major thiol in plasma is cysteine, which is present
at concentrations approximately 10 times greater than
homocysteine. The work described here is therefore only
of relevance if homocysteine is chemically distinct from
cysteine. Recent work [56,57] suggests that the two
compounds have interlinked roles, but with different
reactivity and redox potential, leading to a marked dif-
ferentiation of activity. Reduced homocysteine is exported
continuously in low concentration from endothelial cells,
which may be an important factor in distinguishing its
physiological relevance to cardiovascular disease from
effects of cysteine.References
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